Induction therapy for class I/II lupus nephritis with glucocorticoid monotherapy associates with higher relapse and poorer kidney outcomes
Class I/II LN patients treated with GC monotherapy have higher renal relapse rates and poorer long-term renal outcomes compared with those receiving GC in combination with other immunosuppressants as induction therapy.
Authors
- Ruihan Tang (ORCID: https://orcid.org/0000-0001-5250-6239)
- Huajing Peng
- Hongjian Ye (ORCID: https://orcid.org/0000-0002-9565-508X)
- Xin Wang (ORCID: https://orcid.org/0000-0002-6072-599X)
- Xiang Wang (ORCID: https://orcid.org/0000-0003-0992-8553)
- Xiuzhi Jia (ORCID: https://orcid.org/0000-0003-3809-392X)
- Jianwen Yu
- Wei Chen (ORCID: https://orcid.org/0000-0001-7194-8040)
- Xi Xia (ORCID: https://orcid.org/0000-0003-3146-5567)
- Haishan Wu (ORCID: https://orcid.org/0000-0002-3070-3925)
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1093/ckj/sfaf171
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- National Health Commission of the People's Republic of China